The authors reply

New England Journal of Medicine

Volumn 372, Issue 23, 2015, Pages 2269-2270

  Moore, Halle C F ^a   Unger, Joseph M ^b   Albain, Kathy S ^c  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b USA   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; GONADORELIN DERIVATIVE; ANTINEOPLASTIC AGENT; GONADORELIN; GOSERELIN;

AMENORRHEA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; FERTILITY; HUMAN; INFERTILITY THERAPY; LETTER; MENSTRUATION; OBSERVATIONAL STUDY; OVARY INSUFFICIENCY; PREGNANCY OUTCOME; PREGNANCY RATE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGONISTS; BREAST NEOPLASMS; FEMALE; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; PREGNANCY; PRIMARY OVARIAN INSUFFICIENCY;

EID: 84930509026     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1504241     Document Type: Letter

References (2)

1. Azim HA Jr, Kroman N, Paesmans M, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol 2013;31:73-9.
2. Sukumvanich P, Case LD, Van Zee K, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010;116:3102-11.